BA
HZNP

Boston Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Boston Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-24,125
Closed -$437K – 692
2016
Q3 		$437K Buy
24,125
+1,640
+7% +$32K 0.01% 540
2016
Q2 		$370K Buy
22,485
+7,220
+47% +$117K 0.01% 555
2016
Q1 		$253K Hold
15,265
– – 0.01% 614
2015
Q4 		$331K Buy
+15,265
New +$297K 0.01% 557

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Advisors's HZNP Position: Q4 2016 in Review

Boston Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2016, closing a stake of 24,125 shares — an estimated $437K sold.

Boston Advisors first reported a position in HZNP in Q4 2015 and held it in 4 quarters. The position peaked at $437K in Q3 2016. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

  • Boston Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2016 after selling out during the quarter.
  • Boston Advisors sold 24,125 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $437K.
  • Boston Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 4 quarters.
  • Boston Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $437K in Q3 2016.
  • 234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on Boston Advisors's 13F filing for Q4 2016, filed 25 Jan 2017.